Compare VERA & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERA | TWST |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2021 | 2018 |
| Metric | VERA | TWST |
|---|---|---|
| Price | $49.29 | $31.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $67.67 | $46.33 |
| AVG Volume (30 Days) | ★ 1.8M | 1.8M |
| Earning Date | 11-05-2025 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | N/A | $15.19 |
| Revenue Next Year | N/A | $15.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $18.53 | $23.30 |
| 52 Week High | $50.16 | $55.33 |
| Indicator | VERA | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 81.16 | 51.88 |
| Support Level | $40.38 | $31.19 |
| Resistance Level | $47.10 | $33.31 |
| Average True Range (ATR) | 3.45 | 1.68 |
| MACD | 1.26 | 0.12 |
| Stochastic Oscillator | 91.67 | 53.72 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.